Monte Rosa Therapeutics Stock Forecast

Stock Price Forecast

According to 8 analysts polled by S&P Global, Monte Rosa Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $33.17. The average 1-year stock price forecast is 43.97% higher than the current stock price, while the lowest is $29 (+25.87%) and the highest is $37 (+60.59%).

Price Target: $33.17 (+43.97%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$29	$33.17	$33	$37
Change	+25.87%	+43.97%	+43.23%	+60.59%

Analyst Ratings

The average analyst rating for Monte Rosa Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	6	6	6	6	6	6
Buy	2	2	2	2	2	2
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	8	8	8	8	8	8

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Michael Schmidt Guggenheim	Guggenheim	Buy Maintains $30 → $35	Buy	Maintains	$30 → $35	+51.91%	Jun 30, 2026
Derek Archila Wells Fargo	Wells Fargo	Buy Reiterates $29	Buy	Reiterates	$29	+25.87%	Jun 24, 2026
Brian Cheng J.P. Morgan	J.P. Morgan	Buy Reiterates $30 → $31	Buy	Reiterates	$30 → $31	+34.55%	May 11, 2026
Robert Driscoll Wedbush	Wedbush	Buy Maintains $37	Buy	Maintains	$37	+60.59%	May 8, 2026
Edward Tenthoff Piper Sandler	Piper Sandler	Buy Reiterates $37	Buy	Reiterates	$37	+60.59%	May 8, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

44.48M

from 123.67M

-64.04%

from 123.67M

Revenue Next Year

58.17M

from 44.48M

30.79%

from 44.48M

EPS This Year

-1.59

from -0.46

EPS Next Year

-1.81

from -1.59

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	-	-	75.62M	123.67M	44.48M
Revenue Growth	-	-	-	-	63.54%	-64.04%
Operating Income	-72.88M	-112.38M	-143.31M	-81.11M	-54.21M	-186.90M
Net Income	-73.96M	-108.50M	-135.35M	-72.70M	-38.63M	-167.30M
EPS	-	-	-	-	-0.46	-1.59
Free Cash Flow	-61.29M	-72.40M	-53.37M	66.98M	-129.08M	3.00M
No. Analysts	-	-	-	-	-	7

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	191.0M
Avg	44.5M
Low	4.0M

Revenue Growth

Revenue Growth	2026	2027	2028
High	54.4%
Avg	-64.0%
Low	-96.8%

EPS Forecast

EPS	2026	2027	2028
High	-0.24
Avg	-1.59
Low	-2.24

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-